Tirzepatide
Approvedaka Mounjaro, Zepbound, LY3298176
Approved dual agonist (GLP-1 and GIP). Currently the strongest thing you can get with a prescription.
Mechanism
Hits GLP-1 and GIP together. You get tighter blood sugar control and serious appetite suppression, which is why the weight loss outpaces plain semaglutide for most people.
Regulatory & Safety Status
Properly approved: Mounjaro for type 2 diabetes, Zepbound for obesity. This is a real prescription drug, not a research chemical.
Research
Clinical evaluation and treatment of obesity in women across selected life stages: a narrative review
Preconception incretin therapy reduces pregnancy and cardiometabolic outcomes in polycystic ovary syndrome
Tirzepatide-induced pneumatosis intestinalis: a rare but clinically significant gastrointestinal adverse effect
Comparison of cardiometabolic benefits and tolerability in patients on sustained low doses of semaglutide or tirzepatide
SURMOUNT-1 obesity trial
Pivotal phase 3 trial in adults with obesity.
Latest tirzepatide research
In the News
FDA confirms semaglutide and tirzepatide off the drug shortage list
Supply is back, so the compounding pharmacies lose the shortage exemption. If you have been getting cheap compounded semaglutide, that tap is closing.
FDA warns consumers against unapproved and compounded GLP-1 products
The agency is flagging dosing mistakes and quality problems with compounded and counterfeit versions. Know your source, or skip it.
Tirzepatide cleared as the first drug for obstructive sleep apnea in obesity
First drug cleared for obstructive sleep apnea in obesity. Tirzepatide keeps picking up indications well beyond weight loss.
GLP-1 demand keeps obesity drugs the dominant pharma growth story
Capacity expansions and the next wave of triple-agonists keep obesity drugs the biggest story in pharma.